Arax Advisory Partners’s Aardvark Therapeutics AARD Stock Holding History

Arax Advisory Partners’s Portfolio AARD Stock Details AARD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.2K	Buy	8,374 +8,350	+34,792%	+$39K	﹤0.01%	3289
2026 Q1	$23	Buy	+24	New	+$249	﹤0.01%	3711
2025 Q4	–	Sell	-21	Closed	-$280	–	4624
2025 Q3	$280	Buy	+21	New	+$237	﹤0.01%	3422

Other funds holding AARD

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Arax Advisory Partners's AARD Position: Q2 2026 in Review

Arax Advisory Partners increased its Aardvark Therapeutics (AARD) stake by 34,792% in Q2 2026, buying an estimated $39K and bringing the position to 8,374 shares worth $48.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3289.

Arax Advisory Partners first reported a position in AARD in Q3 2025 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

Arax Advisory Partners held 8,374 shares of Aardvark Therapeutics worth $48.2K as of Q2 2026.
Arax Advisory Partners bought 8,350 Aardvark Therapeutics shares in Q2 2026, an estimated $39K.
Aardvark Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3289 holding.
Arax Advisory Partners first reported a position in Aardvark Therapeutics in Q3 2025 and has held it in 3 quarters since.
71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.